Retatrutide, by Soma Pharmaceuticals , is attracting increasing attention as a innovative treatment for obesity control . This innovative compound combines the activity of a GLP-1 receptor agonist and a GIP receptor agonist , aiming to simply promote weight loss but also improve associated metabolic factors. Early human trials have shown impressive